563 related articles for article (PubMed ID: 22524688)
21. Adjuvant sorafenib after heptectomy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma patients.
Xia F; Wu LL; Lau WY; Huan HB; Wen XD; Ma KS; Li XW; Bie P
World J Gastroenterol; 2016 Jun; 22(23):5384-92. PubMed ID: 27340354
[TBL] [Abstract][Full Text] [Related]
22. Validation of three staging systems for hepatocellular carcinoma (JIS score, biomarker-combined JIS score and BCLC system) in 4,649 cases from a Japanese nationwide survey.
Kitai S; Kudo M; Izumi N; Kaneko S; Ku Y; Kokudo N; Sakamoto M; Takayama T; Nakashima O; Kadoya M; Matsuyama Y; Matsunaga T
Dig Dis; 2014; 32(6):717-24. PubMed ID: 25376289
[TBL] [Abstract][Full Text] [Related]
23. Intermediate-advanced hepatocellular carcinoma in Argentina: Treatment and survival analysis.
Piñero F; Marciano S; Fernández N; Silva J; Anders M; Zerega A; Ridruejo E; Romero G; Ameigeiras B; D'Amico C; Gaite L; Bermúdez C; Reggiardo V; Colombato L; Gadano A; Silva M
World J Gastroenterol; 2019 Jul; 25(27):3607-3618. PubMed ID: 31367160
[TBL] [Abstract][Full Text] [Related]
24. External validation of a simplified BCLC staging system for early hepatocellular carcinoma.
Santambrogio R; Salceda J; Costa M; Kluger MD; Barabino M; Laurent A; Opocher E; Azoulay D; Cherqui D
Eur J Surg Oncol; 2013 Aug; 39(8):850-7. PubMed ID: 23726257
[TBL] [Abstract][Full Text] [Related]
25. Clinical outcomes and prognostic factors of patients with advanced hepatocellular carcinoma treated with sorafenib as first-line therapy: a Korean multicenter study.
Lee S; Kim BK; Kim SU; Park SY; Kim JK; Lee HW; Park JY; Kim DY; Ahn SH; Tak WY; Kweon YO; Lee JI; Lee KS; Kim HJ; Han KH
J Gastroenterol Hepatol; 2014; 29(7):1463-9. PubMed ID: 25273508
[TBL] [Abstract][Full Text] [Related]
26. BCLC stage B is a better designation for single large hepatocellular carcinoma than BCLC stage A.
Jung YK; Jung CH; Seo YS; Kim JH; Kim TH; Yoo YJ; Kang SH; Yim SY; Suh SJ; An H; Yim HJ; Yeon JE; Byun KS; Um SH
J Gastroenterol Hepatol; 2016 Feb; 31(2):467-74. PubMed ID: 26332049
[TBL] [Abstract][Full Text] [Related]
27. Prospective validation of the Barcelona Clinic Liver Cancer staging system.
Cillo U; Vitale A; Grigoletto F; Farinati F; Brolese A; Zanus G; Neri D; Boccagni P; Srsen N; D'Amico F; Ciarleglio FA; Bridda A; D'Amico DF
J Hepatol; 2006 Apr; 44(4):723-31. PubMed ID: 16488051
[TBL] [Abstract][Full Text] [Related]
28. Can More Aggressive Treatment Improve Prognosis in Patients with Hepatocellular Carcinoma? A Direct Comparison of the Hong Kong Liver Cancer and Barcelona Clinic Liver Cancer Algorithms.
Lee YS; Seo YS; Kim JH; Lee J; Kim HR; Yoo YJ; Kim TS; Kang SH; Suh SJ; Joo MK; Jung YK; Lee BJ; Yim HJ; Yeon JE; Kim JS; Park JJ; Um SH; Bak YT; Byun KS
Gut Liver; 2018 Jan; 12(1):94-101. PubMed ID: 28873509
[TBL] [Abstract][Full Text] [Related]
29. Medical treatments: in association or alone, their roles and their future perspectives: the Western experience.
Reig M; Bruix J
J Hepatobiliary Pancreat Sci; 2010 Jul; 17(4):420-1. PubMed ID: 19890601
[TBL] [Abstract][Full Text] [Related]
30. Comparison of clinical staging systems in predicting survival of hepatocellular carcinoma patients receiving major or minor hepatectomy.
Chen TW; Chu CM; Yu JC; Chen CJ; Chan DC; Liu YC; Hsieh CB
Eur J Surg Oncol; 2007 May; 33(4):480-7. PubMed ID: 17129701
[TBL] [Abstract][Full Text] [Related]
31. Treatment of hepatocellular carcinoma in a tertiary Romanian center. Deviations from BCLC recommendations and influence on survival rate.
Radu P; Groza I; Iancu C; Al Hajjar N; Andreica V; Sparchez Z
J Gastrointestin Liver Dis; 2013 Sep; 22(3):291-7. PubMed ID: 24078986
[TBL] [Abstract][Full Text] [Related]
32. Long-term results of sorafenib in advanced-stage hepatocellular carcinoma: what can we learn from routine clinical practice?
Sacco R; Bargellini I; Ginanni B; Bertini M; Faggioni L; Federici G; Romano A; Bertoni M; Metrangolo S; Altomare E; Parisi G; Tumino E; Scaramuzzino A; Bresci G; Bartolozzi C
Expert Rev Anticancer Ther; 2012 Jul; 12(7):869-75. PubMed ID: 22845401
[TBL] [Abstract][Full Text] [Related]
33. A Proposal for Modification of the Barcelona Clinic Liver Cancer Staging System Considering the Prognostic Implication of Performance Status.
Cho HJ; Kim SS; Kang SY; Yang MJ; Noh CK; Hwang JC; Lim SG; Shin SJ; Lee KM; Yoo BM; Lee KJ; Kim JH; Cho SW; Cheong JY;
Gut Liver; 2019 Sep; 13(5):557-568. PubMed ID: 31023007
[TBL] [Abstract][Full Text] [Related]
34. Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma.
Park JW; Koh YH; Kim HB; Kim HY; An S; Choi JI; Woo SM; Nam BH
J Hepatol; 2012 Jun; 56(6):1336-42. PubMed ID: 22314421
[TBL] [Abstract][Full Text] [Related]
35. Survival benefit of liver resection for Barcelona Clinic Liver Cancer stage B hepatocellular carcinoma.
Kim H; Ahn SW; Hong SK; Yoon KC; Kim HS; Choi YR; Lee HW; Yi NJ; Lee KW; Suh KS;
Br J Surg; 2017 Jul; 104(8):1045-1052. PubMed ID: 28480964
[TBL] [Abstract][Full Text] [Related]
36. Barcelona Clinic Liver Cancer outperforms Hong Kong Liver Cancer staging of hepatocellular carcinoma in multiethnic Asians: Real-world perspective.
Li JW; Goh BG; Chang PE; Tan CK
World J Gastroenterol; 2017 Jun; 23(22):4054-4063. PubMed ID: 28652658
[TBL] [Abstract][Full Text] [Related]
37. Prognosis of unresectable hepatocellular carcinoma: comparison of seven staging systems (TNM, Okuda, BCLC, CLIP, CUPI, JIS, CIS) in a Chinese cohort.
Zhang JF; Shu ZJ; Xie CY; Li Q; Jin XH; Gu W; Jiang FJ; Ling CQ
PLoS One; 2014; 9(3):e88182. PubMed ID: 24609114
[TBL] [Abstract][Full Text] [Related]
38. Sorafenib after resection improves the outcome of BCLC stage C hepatocellular carcinoma.
Li J; Hou Y; Cai XB; Liu B
World J Gastroenterol; 2016 Apr; 22(15):4034-40. PubMed ID: 27099447
[TBL] [Abstract][Full Text] [Related]
39. Comparison of seven prognostic staging systems in patients who undergo hepatectomy for hepatocellular carcinoma.
Kondo K; Chijiiwa K; Nagano M; Hiyoshi M; Kai M; Maehara N; Ohuchida J; Nakao H; Ohkuwa Y
Hepatogastroenterology; 2007; 54(77):1534-8. PubMed ID: 17708292
[TBL] [Abstract][Full Text] [Related]
40. Prognostic factors of survival in patients with non-resectable hepatocellular carcinoma: hepatitis C versus miscellaneous etiology.
Abbas Z; Siddiqui AU; Luck NH; Hassan M; Mirza R; Naqvi A; Rizvi AH
J Pak Med Assoc; 2008 Nov; 58(11):602-7. PubMed ID: 19024130
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
